CDSCO Modifies Norms for Testing Permissions to Speed Up Drug Approvals
The Central Drugs Standard Control Organisation (CDSCO) announced modifications to the process for granting No Objection Certificates (NOCs) for laboratory testing of drug samples, with the changes coming into effect from June 1, 2026.
Under the revised norms, any NOC for testing of drug samples at designated government laboratories will be issued immediately upon receipt of applications — eliminating the earlier practice of detailed pre-scrutiny before granting permission.
Previously, CDSCO examined detailed product specifications submitted by applicants before issuing testing permissions — including type of formulation, dosage form, Critical Quality Attributes (CQAs), product development reports, forced degradation studies, and other technical data.
Under the new system, applicants must submit finalised regulatory specifications upfront at the time of applying, based on prevailing Pharmacopoeia standards and their own Quality Management System (QMS) — shifting the technical scrutiny to a later stage rather than front-loading it as a gate for testing.
The move is aimed at reducing the time taken between application and the commencement of laboratory testing, thereby speeding up the overall drug approval timeline for both imported and domestically manufactured drugs.
This change is part of a broader push to streamline pharmaceutical regulations under the New Drugs and Clinical Trials (Amendment) Rules, 2026 and to make India a more competitive destination for drug development and clinical research.
CDSCO: India's National Drug Regulatory Authority
The Central Drugs Standard Control Organisation (CDSCO) functions as India's National Regulatory Authority (NRA) for pharmaceuticals and medical devices. It operates under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare. The Drugs Controller General of India (DCGI) heads CDSCO and is the apex drug regulatory official.
The NOC modification is a CDSCO administrative decision that does not require a legislative change — it adjusts the internal scrutiny process. However, the broader New Drugs and Clinical Trials (Amendment) Rules, 2026 under which it sits do involve formal rule-making under the Drugs and Cosmetics Act, requiring DTAB consultation.
Drugs and Cosmetics Act, 1940: Regulatory Architecture
The Drugs and Cosmetics Act, 1940 is the foundational legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India. Passed during the colonial period and extensively amended since, it establishes a dual regulatory structure where the Central Government (through CDSCO/DCGI) and State Governments (through State Drug Controllers/SDCs) share jurisdiction.
The revised NOC process for testing permissions directly involves the Central Drug Testing Laboratories. By allowing immediate NOC issuance, CDSCO is decoupling the administrative permission step from the technical scrutiny step — a process innovation within the existing legislative framework of the Drugs and Cosmetics Act.
India's Pharmaceutical Sector: Global Position and Policy Context
India is the world's third-largest pharmaceutical producer by volume and holds approximately 20% of the global generics market by volume. The sector contributes around $27 billion in exports annually (2023-24), making it one of India's top export earners. "Pharmacy of the World" is a widely used descriptor reflecting India's role as a key supplier of generic medicines to developing countries and multilateral procurement agencies.
The NOC modification is a targeted operational reform addressing one specific bottleneck in the approval chain. It fits within the broader strategic priority of reducing regulatory friction for India's pharmaceutical sector — particularly for companies seeking to test new formulations for both domestic market approval and export registration in regulated markets (US, EU, WHO prequalification).
Quality Management in Pharmaceuticals: GMP and Pharmacopoeia Standards
Good Manufacturing Practice (GMP) and pharmacopoeia compliance are the twin pillars of pharmaceutical quality assurance. The Drugs and Cosmetics Rules, 1945, Schedule M sets out GMP requirements for pharmaceutical manufacturers in India. The World Health Organization's (WHO) prequalification programme and the US FDA's registration process both require GMP compliance verified through inspections.
The new CDSCO norm requires applicants to base their testing specifications on:
- Prevailing Pharmacopoeia standards (Indian Pharmacopoeia, British Pharmacopoeia, United States Pharmacopeia) and relevant general chapters listed in the Second Schedule of the Drugs and Cosmetics Act, 1940
- A Product-Specific Quality Management System (QMS) — a documented system ensuring consistency between the development process and the submitted specifications
Key Details
- Indian Pharmacopoeia (IP): monographs for ~3,500 drugs; published by IPC under Ministry of Health
- Schedule M of D&C Rules: prescribes GMP for pharmaceutical manufacturing units; aligned with WHO GMP guidelines (2014)
- Critical Quality Attributes (CQAs): physical, chemical, biological properties critical to product quality (e.g., potency, purity, dissolution rate)
- Quality Management System (QMS): ISO 9001 / ICH Q10 pharmaceutical quality system guidelines
- WHO prequalification: mandatory for supplying medicines to UNICEF, Global Fund, PEPFAR procurement — key for Indian pharma exports
- ICH (International Council for Harmonisation): sets globally harmonised pharmaceutical quality, safety, and efficacy guidelines; India became member in 2016
The shift to upfront, complete specification submission under the new CDSCO norms incentivises companies to prepare more rigorous, pharmacopoeia-compliant specification documents before applying — rather than submitting incomplete data for iterative pre-scrutiny. This places greater responsibility on applicants but removes a gatekeeping step that slowed file movement without adding testing quality.
- Issuing authority: Central Drugs Standard Control Organisation (CDSCO), under Ministry of Health and Family Welfare
- Change: Immediate NOC issuance for laboratory testing upon application receipt — eliminating pre-scrutiny of detailed product specifications
- Effective date: June 1, 2026
- Part of: New Drugs and Clinical Trials (Amendment) Rules, 2026
- Applicants must now submit: finalised regulatory specifications based on Pharmacopoeia standards and product-specific QMS upfront
- Earlier requirement (removed): detailed product development reports, forced degradation studies, Critical Quality Attributes (CQAs), dosage form data before NOC
- Governing legislation: Drugs and Cosmetics Act, 1940; New Drugs and Clinical Trials (NDCT) Rules, 2019 (as amended 2026)
- CDSCO structure: HQ New Delhi; 8 Zonal Offices; 6 Sub-Zonal Offices; 8 Central Drug Testing Laboratories; 16 Port Offices
- India's pharma export value: ~$27 billion (2023-24); world's third-largest pharma producer by volume
- India supplies ~50% of Africa's drug needs and ~40% of US generics by volume
- API vulnerability: India imports ~68-70% of active pharmaceutical ingredients from China